Two-ingredient formulation: Contains tirzepatide and retatrutide, as confirmed by the supplier. Refer to the product label for the quantity of each ingredient.

60 mg listed quantity: The product is listed as TirReta 60 mg. This designation is not an individual dose and does not specify the ingredient ratio or concentration after preparation.

Self-mix format: Requires preparation rather than being supplied ready-mixed. Product-specific preparation requirements must be confirmed before handling.

Noventra Pharma product: Listed as Noventra Pharma TirReta 60 mg Self-Mix.

Linked research references: The Research section includes publications examining tirzepatide and retatrutide separately. These studies do not establish the safety or effectiveness of this combination or this specific product.

Product-specific storage and handling: Follow the manufacturer’s documentation, including requirements after preparation. Do not assume that diluent or mixing accessories are included unless explicitly listed.

Mixing Instructions

• Mix 60 mg with 2 mL injectable water.
• 10 units = 1.5 mg.

Protocol

• Week 1: 2.5 mg — 16.5 units
• Week 2: 5 mg — 33 units
• Week 3: 5 mg — 33 units
• Week 4: 7.5 mg — 50 units
• Week 5: 7.5 mg — 50 units

Maintenance

- 7.5 mg — 50 units

What is Noventra Pharma TirReta 60 mg Self-Mix?

TirReta is listed as a Noventra Pharma product in a self-mix format, with a stated quantity of 60 mg. Consult the product label and manufacturer’s documentation for its exact ingredients and specifications.

What does self-mix mean?

Self-mix indicates that preparation is required rather than the product being supplied ready-mixed. It does not establish suitability for self-administration. Do not prepare the product without verified, product-specific instructions and appropriate professional guidance.

Does 60 mg mean one dose?

No. The 60 mg designation is the quantity stated in the listing, not a recommended individual dose. It does not specify the concentration after preparation or the amount of each ingredient.

Which ingredients are included?

Do not infer the formulation or ingredient proportions from the TirReta name. Confirm the ingredient names and individual quantities using the manufacturer’s label and product documentation before purchase.

Are diluent and mixing accessories included?

Only items explicitly listed in the pack contents should be considered included. Confirm with the supplier whether diluent, mixing accessories, or other equipment are supplied.

How should the product be stored?

Follow the storage conditions on the product label and accompanying documentation, including any separate requirements after preparation. Do not use storage instructions from another product. Ask the supplier if the requirements are unclear.

Where can I find preparation or dosing instructions?

This FAQ does not provide mixing quantities, dosing, or administration instructions. Refer to verified product-specific documentation and consult a qualified healthcare professional. Do not guess preparation quantities or use an online regimen for another product.

What if the packaging is damaged or the label is incomplete?

Do not use or prepare the product. Contact the supplier to resolve packaging concerns or obtain complete product information first.

TirReta — Research Background

TirReta is described by the supplier as containing tirzepatide and retatrutide. The publications below examine these compounds separately under controlled clinical trial conditions. They do not evaluate this TirReta 60 mg self-mix product or the combination of its ingredients.

Tirzepatide: SURMOUNT-1 clinical trial

This phase 3 randomized, placebo-controlled trial studied tirzepatide over 72 weeks in 2,539 adults with obesity, or overweight with a weight-related complication, excluding diabetes. Researchers assessed changes in body weight and safety. Gastrointestinal adverse events were common, and some participants discontinued treatment because of adverse events.

Read: Tirzepatide Once Weekly for the Treatment of Obesity — New England Journal of Medicine (2022).

R3t@trutide: Phase 2 clinical trial

This randomized, placebo-controlled phase 2 trial studied retatrutide in 338 adults with obesity, or overweight with a weight-related condition, over 48 weeks. Researchers assessed changes in body weight and safety. Reported adverse events included gastrointestinal effects, and dose-dependent increases in heart rate were observed.

Read: Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial — New England Journal of Medicine (2023).

How to Interpret This Research

Results from studies of each compound separately cannot establish that combining them is safe, effective, or more beneficial. These publications do not verify the identity, ingredient proportions, purity, sterility, stability, or effectiveness of this specific self-mix product, or its equivalence to trial formulations.

Important Information

These references are provided for background reading, not as mixing, dosing, or administration instructions. Do not use trial regimens to prepare or administer TirReta. Confirm product-specific documentation and consult a qualified healthcare professional.